Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway
International Immunopharmacology · 2024-11 · 141 · 112775
DOI: 10.1016/j.intimp.2024.112775 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-11. Verfasst von Chunhong Liao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery Ward I Minimally Invasive Surgery& Bariatric Metabolic Surgery, Hunan Provincial People's Hospital (The First Aff…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, B7-H1 Antigen, Liver Neoplasms, Mice, Inbred BALB C. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer that is fatal and has a dismal prognosis. Obovatol (Ob), a novel lignan derived from the leaf and stem bark of Magnolia obovata Thunb, has exhibited anti-tumor effect on diverse tumors. However, its effect and mechanisms on HCC remain to be further explored. METHODS: Huh7 and Hep3B cells, as well as BALB/c nude mice were used to determine the function and mechanisms of Ob on growth, invasion and immune escape by cell counting kit-8, transwell, enzyme-linked immunosorbent assay (ELISA) and western blot experiments. RESULTS: Ob reduced the cell viability of Huh7 and Hep3B cells, with a IC50 value of 57.41 µM and 62.86 µM, respectively. Ob declined the invasion ability, the protein expression of N-cadherin and the concentrations of IL-10 and TGF-β, whereas increased the E-cadherin expression and the contents of IFN-γ and IL-2 in Hep3B and Huh7 cells. Mechanically, Ob decreased the protein level of p-JAK/JAK, p-STAT3/STAT3 and PD-L1, which was partly restored with the treatment of RO8191, an activator of JAK/STAT3 axis. The effect of Ob on the cell viability, the invasion ability, the protein level of N-cadherin and E-cadherin, and the concentrations of IL-10, TGF-β, IFN-γ and IL-2 in both Hep3B and Huh7 cells was reversed with the management of RO8191. In vivo, Ob reduced tumor volume and weight, the level of N-cadherin, PD-L1, p-JAK/JAK, and p-STAT3/STAT3, with an elevated expression of E-cadherin and IFN-γ. CONCLUSION: Ob downregulated the JAK/STST3/PD-L1 pathway to attenuate the growth, invasion and immune escape of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery Ward I Minimally Invasive Surgery& Bariatric Metabolic Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Human 410005, PR China.
- Department of Hepatobiliary Surgery, Changsha County People's Hospital, Human, PR China.
- Hunan Normal University, Human, 410005, PR China.
- Department of Hepatobiliary Surgery Ward I Minimally Invasive Surgery& Bariatric Metabolic Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Human 410005, PR China.…
Zitieren
APA
Liao, C., Zhao, M., Jiang, X., Sun, W., Zeng, Q., Cai, C., & Yin, X. (2024). Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway. International Immunopharmacology, 141, 112775. https://doi.org/10.1016/j.intimp.2024.112775
Vancouver
Liao C, Zhao M, Jiang X, Sun W, Zeng Q, Cai C, et al. Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway. International Immunopharmacology. 2024;141:112775. doi:10.1016/j.intimp.2024.112775
BibTeX
@article{Liao2024,
author = {Liao, Chunhong and Zhao, Min and Jiang, Xiao and Sun, Wei and Zeng, Qihong and Cai, Chengzhi and Yin, Xinmin},
title = {Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway},
journal = {International Immunopharmacology},
year = {2024},
volume = {141},
pages = {112775},
doi = {10.1016/j.intimp.2024.112775}
}
EUVIMED